SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting SARS-CoV with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC50=26.5 µM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC50=17.0 µM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 µM[1].
Molecular Weight:
494.58
Formula:
C34H26N2O2
Target:
SARS-CoV
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
